Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Immutep Limited

INVESTOR PRESENTATION - Immutep Limited

ASX:IMM

Immutep Limited

Health

Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Read more

Market Cap

$291.93m

Price at Close

$0.45

4w avg. Volume

1.99m

4w avg. Turnover

$819.93k

Announcements
announcementt+2 movementdate
  • Recruitment of head & neck cancer patients completed for ph2

    Progress Report · Market sensitive

  • +3.70%

    06 Jan 2021

+3.70%

06 Jan 2021
  • Resignation and Appointment of Joint Company Secretary

    Company Administration

  • -2.41%

    04 Jan 2021

-2.41%

04 Jan 2021
  • Change in substantial holding

    Shareholder Details

  • -2.41%

    03 Jan 2021

-2.41%

03 Jan 2021
  • Appendix 2A

    Issued Capital

  • 0.00%

    31 Dec 2020

0.00%

31 Dec 2020
  • Change in substantial holding

    Shareholder Details

  • -1.19%

    30 Dec 2020

-1.19%

30 Dec 2020
  • Change in substantial holding

    Shareholder Details

  • +6.41%

    29 Dec 2020

+6.41%

29 Dec 2020
  • Immutep granted US patent for eftilagimod alpha with a PD-1

    Progress Report · Market sensitive

  • +6.41%

    29 Dec 2020

+6.41%

29 Dec 2020
  • Change in substantial holding

    Shareholder Details

  • +6.41%

    28 Dec 2020

+6.41%

28 Dec 2020
  • Change of Director's Interest Notice - Dr Howard

    Shareholder Details

  • +7.69%

    24 Dec 2020

+7.69%

24 Dec 2020
  • Appendix 2A

    Issued Capital

  • +7.69%

    24 Dec 2020

+7.69%

24 Dec 2020
Market Data

Current Price

$0.45

52WK HIGH

$0.63

52WK LOW

$0.1

1YR RETURN

+50.00%

1YR RETURN VS. SECTOR

+12.49%

90 DAY RETURN

+80.00%

ASX RANK

516

/2,047

SECTOR RANK

35

/168

SHARES OUTSTANDING

648.73m
ASX:IMM

Immutep Limited

Health

Immutep Limited are a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, with operations in Europe, Australia, and the U.S. They are the global leader in the understanding of and in the development of therapeutics that modulate Lymphocyte Activation Gene-3 (“LAG-3”), a cell surface molecule which plays a vital role in regulating T cells and which was discovered by their Chief Scientific Officer and Chief Medical Officer Dr. Frederic Triebel. Their objective is to harness and strengthen the power of patients’ immune systems through therapeutic intervention for the benefit of patients’ health. They have one pre-clinical and three clinical LAG-3 product candidates under development, including two antibodies for modulating immune responses in autoimmunity and cancer, through pharmaceutical partnerships, with Novartis and GlaxoSmithKline.

Read more

Market Cap

$291.93m

Price at Close

$0.45

4w avg. Volume

1.99m

4w avg. Turnover

$819.93k

ASX:IMM is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.